All In Biotech

Free tool

FAERS Monitor: Somatuline Depot

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022074 or its brand name (Somatuline Depot, Lanreotide Acetate). Reports on generic versions are filed under their own applications.

Reports

7,953

Serious

4,731

59% of reports

Hospitalization

1,619

Death reported

1,485

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,514
  • diarrhoea1,440
  • death1,278
  • fatigue983
  • nausea735
  • injection site pain601
  • abdominal pain573
  • headache507
  • malaise446
  • dizziness422
  • asthenia418
  • weight decreased409
  • pain399
  • product dose omission issue388
  • injection site mass377

Reports by year received

View as table
YearReports
20062
20074
200815
20094
201078
201167
201275
201341
201431
201526
201641
20171,043
2018237
2019277
2020360
2021973
20221,265
20231,154
2024836
2025913
2026511

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,206 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site massSignal37727.224.79,419
abdominal painSignal5736.56.02,700
diarrhoeaSignal1,4405.95.66,042
injection site painSignal6015.24.82,055
off label useSignal1,5144.64.44,408
deathSignal1,2783.93.72,900
weight decreasedSignal4093.93.5881
product dose omission issueSignal3883.53.2697
fatigueSignal9833.33.21,671
astheniaSignal4182.92.7543
malaiseSignal4462.72.5482
nauseaSignal7352.52.3658
dizzinessSignal4222.22.0295
headacheSignal5072.12.0316
pain3991.71.6123

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.